Prosecution Insights
Last updated: November 20, 2026
Application No. 18/965,997

Left Atrial Appendage Occluder Hook Placement

Final Rejection §102§103
Filed
Dec 02, 2024
Priority
Mar 25, 2024 — provisional 63/569,321
Examiner
BYRD, BRIGID K
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Abbott Laboratories
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
10m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
237 granted / 332 resolved
+1.4% vs TC avg
Strong +46% interview lift
Without
With
+46.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
37 currently pending
Career history
386
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
38.8%
-1.2% vs TC avg
§102
26.8%
-13.2% vs TC avg
§112
28.4%
-11.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 332 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment This Office Action is a response to applicant’s arguments and amendment filed 09/08/2026. Claims 1, 4, 7 and 15-18 are amended. Claims 8-14 are cancelled. Claims 1-7 and 15-20 are currently pending. The objection of claims 1, 8 and 11 has been withdrawn due to applicant’s amendment. The rejection of claims 4-5 and 7-20 under 35 U.S.C. 112(b) has been withdrawn due to applicant’s amendment. Response to Arguments Applicant’s arguments, see Remarks, filed 09/08/2026, with respect to the rejection(s) of claim(s) 15-20 under 35 U.S.C. 102(a)(1) as being anticipated by Amplatz; claims 1-10 and 12-14 under 35 U.S.C. 103 as being unpatentable over Morin; and claim 11 under 35 U.S.C. 103 as being unpatentable over Morin in view of Kreidler, have been fully considered but are not persuasive. The rejection has been modified, necessitated by applicant’s amendment to the claims. 1) Applicant argues Amplatz does not disclose the proximal end of the lobe remaining collapsed within the delivery catheter, and while in this partially expanded state, contacting the hooks with tissue of the LAA (Remarks, pgs. 5-6). Applicant further argues the disclosure of Amplatz does not teach the proximal end of the lobe remaining collapsed, and hooks 20 of Amplatz are not shown as extending radially outward of the radially-outer-most extent of lobe 12. In response to applicant’s first argument, it is respectfully submitted Amplatz states the device exits the distal end of the delivery catheter and resiliently returns to an expanded shape, and further discloses the ability to pull the device proximally back within the delivery system (paras. [0056] and [0058]). Further, para. [0059] describes the distal end of the device urged out from the catheter to elastically self-expand and contact the vessel walls, and para. [0063] describes the device beginning to exit the distal end of the catheter. Therefore, Amplatz is considered to disclose staged expansion, starting with the distal end of the device, in which the hooks engage tissue upon release from the delivery catheter. Accordingly, the distal end of the device is considered to be released before the proximal end of the device, such that the claim limitation is met. Further, applicant states hooks 20 are shown as not extending radially outward of lobe 12, however this is not claimed, nor do the figures of Amplatz specifically depict this. In contrast, fig. 8 appears to depict hooks 20 radially outward of lobe 12. 2) Applicant further argues Amplatz does not disclose the hooks in engagement with tissue when the lobe is partially expanded (Remarks, pg. 6). In response to applicant’s second argument, it is respectfully submitted Amplatz discloses staged expansion as discussed above, and further discloses the hooks engaging tissue prior to full expansion of the device (para. [0067]). Accordingly, the claim limitation is considered to be met, because Amplatz discloses the hooks engaging tissue prior to full release of the device. Further, Amplatz is silent as to any disengagement of the already engaged hooks to tissue. 3) Applicant further argues Amplatz does not disclose a valley as claimed (Remarks, pgs. 6-7). In response to applicant’s third argument, it is respectfully submitted the rejection has been modified, necessitated by applicant’s amendments to the claims. Under broadest reasonable interpretation, a valley can be defined as a hollow or depression (see Merriam-Webster dictionary definition). Based on fig. 1a of Amplatz, the valley of transition segment 19 is a hollow or depression lying between the proximal end of lobe 12 and the distal end of disk 14, such that transition segment 19 is considered to meet the claim language of a valley as discussed below. 4) Applicant further argues the instant spec. provides criticality for the claimed range of the position of the hooks (Remarks, pgs. 7-8). In response to applicant’s fourth argument, it is respectfully submitted para. [0046] of the instant spec. describes the claimed range as having a relationship that “may be at least partly responsible for the functionality”, and further expands on the ranges by describing them as exemplary and not required for the invention (e.g. “may have a distance”). This does not demonstrate specific operability of the device within the claimed range, or describe how the claimed range achieves unexpected results (see MPEP 2144.05(III)(A)). Accordingly, the rejection is maintained. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: “connecting member” in claims 6 and 19. Para. [0032] of the published application describes the “connecting member” as structure 120 (see figs. 5-6). “Connecting member” uses the generic placeholder “member” coupled with the term “connecting”, which is functional in that the limitation alternatively recites a member for connecting, and the term “member” is not preceded by a structural modifier since the term “connecting” does not imply any structure. Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 15-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Amplatz (US 2009/0171386 A1) (all references previously of record). Regarding claim 15, Amplatz discloses (see abstract; paras. [0029]-[0069]; figs. 1a-11) a method for occluding a left atrial appendage (“LAA”) (figs. 3a-c), the method comprising: positioning an occluder (10, para. [0040]; fig. 1a) in a collapsed condition within a delivery catheter (loaded into lumen 25 of delivery catheter 29, para. [0054]; fig. 2), the occluder including: a lobe (12, para. [0040]) having a proximal end defining a proximal surface of the lobe (proximal end of 12), a distal end defining a distal surface of the lobe (distal end of 12), and a middle portion connecting and extending between the proximal end and the distal end (depicted in fig. 1a); and a plurality of stabilizing wires (20, para. [0041]) coupled to the lobe (figs. 1a-11), each of the plurality of stabilizing wires having a hook at a distal end thereof (see figs. 4-7); advancing the occluder into or adjacent to the LAA while the occluder is collapsed within the delivery catheter (paras. [0060]-[0061]); transitioning the lobe into a partially-expanded state (partially expanded into LAA, considered to be partially expanded state, para. [0067]) in which the distal end of the lobe has exited the delivery catheter and has begun to self-expand while the proximal end of the lobe remains collapsed within the delivery catheter (considered to include staged expansion in which proximal end is released after distal end of 12, para. [0067]; figs. 10-11); while the lobe is in the partially expanded state, contacting at least one of the hooks with tissue of the LAA (para. [0067]); and after contacting the at least one of the hooks with tissue of the LAA, fully deploying the occluder from the delivery catheter (hooks engage tissue as body member 12 expands before full release, para. [0067]). Regarding claim 16, Amplatz discloses the method of claim 15. Amplatz further discloses wherein between the partially expanded state of the lobe and the full deployment of the occluder from the delivery catheter, the at least one of the hooks remains in contact with the tissue of the LAA (further fixates device 10, para. [0067]). Regarding claim 19, Amplatz discloses the method of claim 15. Amplatz further discloses wherein fully deploying the occluder from the delivery catheter includes deploying a disc (14, para. [0040]) of the occluder from the delivery catheter (para. [0067]), the disc of the occluder being coupled to the lobe of the occluder by a connecting member (19, para. [0045]). Regarding claim 20, Amplatz discloses the method of claim 19. Amplatz further discloses wherein upon deploying the disc of the occluder, the disc at least partially covers an ostium of the LAA (paras. [0042] and [0067]). Regarding claim 15, Amplatz discloses (see abstract; paras. [0029]-[0069]; figs. 1a-11), under an alternative interpretation with respect to the lobe, a method for occluding a left atrial appendage (“LAA”) (figs. 3a-c), the method comprising: positioning an occluder (10, para. [0040]; fig. 1a) in a collapsed condition within a delivery catheter (loaded into lumen 25 of delivery catheter 29, para. [0054]; fig. 2), the occluder including: a lobe (includes 12 and 14, para. [0040]) having a proximal end defining a proximal surface of the lobe (proximal end of 14), a distal end defining a distal surface of the lobe (distal end of 12), and a middle portion connecting and extending between the proximal end and the distal end (includes transition segment 19, para. [0045]); and a plurality of stabilizing wires (20, para. [0041]) coupled to the lobe (figs. 1a-11), each of the plurality of stabilizing wires having a hook at a distal end thereof (see figs. 4-7); advancing the occluder into or adjacent to the LAA while the occluder is collapsed within the delivery catheter (paras. [0060]-[0061]); transitioning the lobe into a partially-expanded state (partially expanded into LAA, considered to be partially expanded state, para. [0067]) in which the distal end of the lobe has exited the delivery catheter and has begun to self-expand while the proximal end of the lobe remains collapsed within the delivery catheter (considered to include staged expansion in which proximal end is released after distal end of 12, para. [0067]; figs. 10-11); while the lobe is in the partially expanded state, contacting at least one of the hooks with tissue of the LAA (para. [0067]); and after contacting the at least one of the hooks with tissue of the LAA, fully deploying the occluder from the delivery catheter (hooks engage tissue as body member 12 and disk portion 14 expand before full release, para. [0067]). Regarding claim 17, Amplatz discloses the method of claim 15. Amplatz further discloses wherein after fully deploying the occluder from the delivery catheter, compression on the lobe from tissue of the LAA creates a valley within the middle portion of the lobe (defined by transition segment 19, considered to be a valley because transition segment 19 is depressed relative to proximal end of lobe 12 and distal end of disk 14, fig. 1a), such that a portion of the lobe forming the valley is not in contact with tissue of the LAA (depicted in fig. 3c). Regarding claim 18, Amplatz discloses the method of claim 17. Amplatz further discloses wherein while the valley is created within the middle portion of the lobe, the at least one of the hooks remains in contact with the tissue of the LAA (para. [0067]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over Morin (US 2022/0008050 A1). Regarding claim 1, Morin discloses (see abstract; paras. [0019]-[0050]; figs. 3-8) an occluder (110, para. [0031]; fig. 3) for occluding a left atrial appendage (“LAA”) (para. [0022]), the occluder comprising: a lobe (118, para. [0032]; fig. 4) sized and shaped for positioning within the LAA (considered to be sized and shaped for positioning within LAA, para. [0043]), the lobe having a proximal end defining a proximal surface (124) of the lobe, a distal end defining a distal surface (128) of the lobe, and a middle portion (130) connecting and extending between the proximal end and the distal end (fig. 4), wherein the lobe has an expanded condition (expanded configuration, para. [0042]) in the absence of applied forces and a collapsed condition (reduced configuration, para. [0042]) for delivery to the LAA; and a plurality of stabilizing wires (132, para. [0033]) coupled to the lobe (fig. 4), each of the plurality of stabilizing wires having a hook (134) at a distal end thereof (fig. 4), each of the hooks having a terminal end positioned radially outwardly of the lobe in the expanded condition of the lobe and being configured to frictionally engage tissue of the LAA (considered to frictionally engage tissue when retained at target site, paras. [0033] and [0038]), wherein in the expanded condition of the lobe, each of the hooks has a distalmost point (distalmost point of hooks 134, fig. 4), the distalmost point of each of the hooks being positioned a spaced axial distance from the distal surface of the lobe in the expanded condition of the lobe (depicted in fig. 4). Morin further discloses the spaced axial distance relatively similar to the spaced axial distance of the instant spec. (see fig. 5 of the instant spec.). However, Morin fails to explicitly disclose the spaced axial distance being between about 0 mm and about 1.5 mm. It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Morin to have a spaced axial distance of 1 mm which falls within the claimed range of between 0 mm and 1.5mm since it has been held that “where the only difference between the prior art and the claims was a recitation of relative dimensions of the claimed device and a device having the claimed relative dimensions would not perform differently than the prior art device, the claimed device was not patentably distinct from the prior art device” Gardner v. TEC Syst., Inc., 725 F.2d 1338, 220 USPQ 777 (Fed. Cir. 1984), cert. denied, 469 U.S. 830, 225 SPQ 232 (1984). In the instant case, the device of Morin would not operate differently with the claimed axial distance and since the hooks of Morin are intended to be located relative to the distal end of the lobe as depicted in fig. 4, the device would function appropriately having the claimed spaced axial distance. Further, it appears that applicant places no criticality on the range claimed, indicating simply that the diameter “may” be within the claimed ranges and “may” be at least partly responsible for the described functionality (para. [0046] of the published application). Regarding claim 2, Morin (as modified) teaches the occluder of claim 1. Morin (as modified) further teaches wherein the spaced axial distance is about 1.0 mm (combination considered to further teach the spaced axial distance being about 1 mm). Regarding claim 3, Morin (as modified) teaches the occluder of claim 1. Morin further discloses wherein a transition between the middle portion and the distal end of the lobe is curved (T2, para. [0032]; fig. 4), the curve of the transition having a contour length measured between (i) a point at which a distal end of the middle portion joins a proximal end of the curved transition, and (ii) a point at which a distal end of the curved transition joins the distal surface of the lobe (considered to be contour length of transition T2, fig. 4). Regarding claim 4, Morin (as modified) teaches the occluder of claim 3. Morin further discloses wherein in the expanded condition of the lobe, at least one of the hooks crosses from an interior of the lobe to an exterior of the lobe at a crossing point (depicted in fig. 4). However, Morin (as modified) fails to explicitly teach the crossing point being positioned between about 25% and about 50% of the contour length. It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Morin (as modified) to have the crossing point positioned between about 25% and about 50% of the contour length, since it has been held that “where the only difference between the prior art and the claims was a recitation of relative dimensions of the claimed device and a device having the claimed relative dimensions would not perform differently than the prior art device, the claimed device was not patentably distinct from the prior art device” Gardner v. TEC Syst., Inc., 725 F.2d 1338, 220 USPQ 777 (Fed. Cir. 1984), cert. denied, 469 U.S. 830, 225 SPQ 232 (1984). In the instant case, the device of Morin (as modified) would not operate differently with the claimed location of the crossing point, and since the hooks of Morin are intended to cross over the transition T2 as depicted in fig. 4, the device would function appropriately having the claimed location of the crossing point within the transition. Further, it appears that applicant places no criticality on the range claimed, indicating simply that the diameter “may” be within the claimed ranges (para. [0047] of the published application). Regarding claim 5, Morin (as modified) teaches the occluder of claim 4. Morin further discloses wherein the transition has a radius of curvature between about 0.075 inches (1.905 mm) and about 0.125 inches (3.175 mm) (para. [0032]). Regarding claim 6, Morin (as modified) teaches the occluder of claim 1. Morin further discloses wherein the occluder includes a disc (116, para. [0032]) at a proximal end of the occluder (fig. 4), and a connecting member (120) connects the disc and the lobe (para. [0032]). Regarding claim 7, Morin (as modified) teaches the occluder of claim 1. Morin further discloses wherein in a compressed state of the lobe (figs. 5b-6), a valley is formed within the middle portion of the lobe (annotated fig. 5b, note the claim language does not specify the direction the valley extends, such that the middle portion is considered to form a valley at least internally as the proximal and distal surfaces bow outwardly, para. [0039]), and in the compressed state, at least one of the hooks extends farther radially outward from a central longitudinal axis of the lobe than does any structure of the lobe (depicted in figs. 5b-6). PNG media_image1.png 808 848 media_image1.png Greyscale Annotated Figure 5B of Morin Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIGID K BYRD whose telephone number is (571)272-7698. The examiner can normally be reached Mon-Fri 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at (571)-272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIGID K BYRD/Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Dec 02, 2024
Application Filed
Jun 11, 2026
Non-Final Rejection mailed — §102, §103
Sep 08, 2026
Response Filed
Nov 06, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788421
JAW CLOSURE TRANSMISSION SYSTEMS
2y 9m to grant Granted Nov 10, 2026
Patent 12788437
PROTECTIVE DEVICE FOR USE DURING SURGERY
2y 11m to grant Granted Nov 10, 2026
Patent 12778629
DEVICE FOR LOADING HAIR GRAFTS INTO A GRAFT IMPLANTATION INSTRUMENT
5y 7m to grant Granted Nov 03, 2026
Patent 12779170
INTRAVASCULAR LITHOTRIPSY CATHETER
3y 2m to grant Granted Nov 03, 2026
Patent 12778624
Puncture Device And Sheath Tube
3y 0m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+46.4%)
2y 9m (~10m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 332 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month